Searchable abstracts of presentations at key conferences in endocrinology

ea0090p92 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

A study to evaluate clinical and metabolic profile in a type 1 diabetes cohort receiving dpp4 inhibitor plus SGLT2 inhibitor compared to either drug alone as an adjuvant therapy

Dev K Chethan , Kumar Sethi Bipin

Introduction: There is always been a need for safe and effective adjuvant therapy in type 1 Diabetes not just for glycemic control but also for cardio-renal benefits.Objectives: To evaluate whether addition of DPP-4 inhibitors reduces the ketogenic potential of SGLT2i when used as an adjuvant therapy in type 1 Diabetes.Materials & Methods: 20 type 1 Diabetes subjects above 18 years of age with poorly controlled glycemia (HbA1c ...

ea0069p69 | Poster Presentations | SFENCC2020

Isolated Langerhans cell histiocytosis in hypothalamic–pituitary region

Khan Amber , Gnanalingham K , Kearney Tara

Case history: We present a rare case of Langerhans cell histiocytosis (LCH) of pituitary stalk and hypothalamus in a 40 year old lady. She presented with 9 weeks history of a sudden onset of polyuria and polydipsia. She had extreme thirst even during night which led to significant nocturia and tiredness. She denied headache, blurring of vision, galactorrhoea or menstrual irregularity. She had no significant past medical history and was not on any medications. Physical examinat...

ea0063p295 | Pituitary and Neuroendocrinology 1 | ECE2019

Silent, isolated ACTH-deficiency in melanoma patients treated with immune checkpoint inhibitors

Heck Ansgar , Winge-Main Anna K.

Background: The incidence of hypophysitis has increased since the introduction of Immuno-oncologic treatment. Treatment with anti-CTLA-4 (Ipilimumab) and anti-PD-1 has improved the prognosis for patients with malign melanoma drastically, but immune-mediated side effects can occur in any organ, including the thyroid and the pituitary. Headache is considered a key symptom of hypophysitis. Here, we report three cases with silent, isolated ACTH-insufficiency following immunotherap...

ea0044p97 | Diabetes and Cardiovascular | SFEBES2016

SGLT2 inhibitors: results from clinical practice

Border Daniel K. , Barber Thomas M.

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and add...

ea0044p178 | Obesity and Metabolism | SFEBES2016

Dramatic weight loss induced by dapagliflozin and tier 3 obesity service support

Border Daniel K , Barber Thomas M

The importance of weight reduction in the management of diabesity is well-established. However, significant weight loss can be difficult to achieve without bariatric surgery, even within specialist tier 3 obesity services. Here we describe the case of a 52 year old man who presented to weight management clinic. He had made multiple weight loss attempts, but with little success. On presentation, his weight was 140.8 kg with a BMI of 40.3 kg/m2, and he had now been static at thi...

ea0035p901 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

How to get surgical remission rates in ACTH-microadenomas close to 100% using minimally invasive approaches for diagnosis and surgery

Ludecke Dieter K , Crock Patricia A , Saeger Wolfgang

Introduction: Pharmacological treatments are still not ideal in ACTH-microadenomas and transnasal-trans-sphenoidal surgery (TSS) is first choice in the treatment of Cushing’s disease (CD). The question is how can a nearly 100% remission rate be achieved with minimally invasive diagnostic testing and TSS. In the discussion of the main lecture from an expert from the USA in ECE13, it became clear that in many European centres, like ours, the procedures are less invasive. Th...

ea0058p079 | Diabetes | BSPED2018

Maturity onset diabetes of the young (MODY): A report of 7 related and unrelated cases in a university hospital

Nambisan Aparna K R , Kapila Piyusha

Introduction: MODY is a group of monogenic disorders contributing to about 1% of diabetes due to a primary defect in the function of the beta cells of the pancreas. Although increasingly recognised, it is often misdiagnosed as type 1 or Type 2 Diabetes Mellitus(T2DM). We describe 7 cases of MODY of which 6 were genetically confirmed.Case reports: Siblings with loss of function mutation of ABCC8 gen. 2 brothers were diagnosed to have diabetes at 15 and 12...

ea0070aep76 | Adrenal and Cardiovascular Endocrinology | ECE2020

Bronchogenic cyst mimicking adrenal mass

Köseoğlu Derya

Introduction: Primary retroperitoneal bronchogenic cysts are rarely seen. Bronchogenic cysts are mostly benign which originate from the remnants of the primitive foregut during the embryonic development.These lesions can be seen near or inside any organ that originates from the embryonic foregut. Bronchogenic cysts are most often found in the thoracic cavity, especially in the mediastinum. Except this many distant sites, such as abdomen, retroperitoneum,...

ea0033p52 | (1) | BSPED2013

46,XX pure gonadal dysgenesis with tall stature due to an Xq21.2 deletion

Narayanan Vidya K , Tolmie John , Donaldson Malcolm

Introduction: 46,XX gonadal dysgenesis without the phenotype of Turner’s syndrome is described as ‘pure’ and is not usually associated with other anomalies with the exception of the rare Perrault syndrome (46,XX-GD with sensori-neural deafness). We describe a girl in whom tall stature was a dominant feature.Case report: A girl was referred aged 15.6 years with primary amenorrhoea and slim build. Examination showed height 172.5 cm (+1.56 <s...